The multiple-dose pharmacokinetics of fluvoxamine in children and adolescentS

T. ZumBrunnen, Z. Lu, J. Chang, J. Nezamus, M. Eller, M. Labellarte, J. Brennan

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Fluvoxamine (FL) is an SSRI used in the treatment of pediatric OCD. To determine the pharmacokinetics (PK) of FL in children (CH), aged 6-11, and adolescents (AD) aged 12-17 and to compare the PK in AD to the PK of adults, 43 CH and AD patients were enrolled and titrated to a FL dose of 100 and 150 mg twice daily, respectively. PK sampling was conducted after administration of FL doses between 25 mg to 150 mg. PK parameters were calculated and adjusted for body weight. Mean steady-state clearance (CLss) values are given below. Mean CLss (L/h/kg) Dose(mg) 25 50 100 150 Child 0.97 0.43 0.39 NA Adolescent 1.5 1.1 0.61 0.71 Adult NA NA NA 0.46 CLss in CH was 40% to 65% of that observed in AD. CLss was 54% higher in AD compared to adults. FL was well tolerated by the CH and AD population. Based on PK, these results suggest that FL doses up to 300 mg/day, as indicated in adults, may be useful in the treatment of OCD in AD.

Original languageEnglish (US)
Pages (from-to)P82
JournalClinical pharmacology and therapeutics
Issue number2
StatePublished - 2001

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'The multiple-dose pharmacokinetics of fluvoxamine in children and adolescentS'. Together they form a unique fingerprint.

Cite this